一、Symbicort 160/4.5 mcg长期用于改善慢性阻塞性肺病(COPD)的症状,包括慢性支气管炎和肺气肿,以改善呼吸和减少突发事件。 二、Symbicort用于治疗6岁及以上的哮喘患者,这些患者的哮喘无法通过吸入性皮质类固醇(ICS)等哮喘控制药物得到良好控制,或者其哮喘需要同时使用ICS和长效β-受体阻滞剂进行治疗2-肾上腺素能激动剂...
SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce COPD exacerbations. SYMBICORT is NOT indicated for the relief of acute bronchospasm. ...
SYMBICORT160/4.5是唯一可以治疗COPD的药物。 重要的使用限制:不适用于急性支气管痉挛症状的缓解。 4 SYMBICORT在中国上市情况 目前,阿斯利康公司生产的布地奈德福莫特罗粉吸入剂已在中国上市,规格为160微克/4.5微克/吸,60吸/支、80微克/4.5微克/吸,60吸/...
COPD:SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups. Asthma:SYMBICORT is for the treatment of asthma in patients 6 years and older whose asthma is no...
ΔTerms and conditions apply. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support.Click hereto see if you are eligible and to learn more. SYMBICORT 160/4.5 mcg for maintenance treatment of COPD…SEE APPROVED USES...
Breyna ™是一种药物器械组合产品,适用于那些哮喘或慢阻肺 (COPD) 患者,提供 160 mcg/4.5 mcg 和 80 mcg/4.5 mcg 两种剂量规格。Viatris 首席执行官 Michael Goettler 评论说:“ FDA 对Breyna ™的最终批准是 FDA 批准的第一个...
nasal congestion, stomach discomfort, vomiting, and thrush in the mouth and throat APPROVED USES COPD: SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups. ...
吸入器被批准用于两种强度(160/4.5mcg/致动和80/4.5mcg/致动)。 对于哮喘患者,布地奈德和富马酸福莫特罗二水合物口服吸入气雾剂最常见的副作用是鼻咽炎(鼻道和喉咙后部肿胀)、头痛、上呼吸道感染、咽喉(鼻子和嘴巴)疼痛、鼻窦炎、流感、背痛、鼻塞、胃部不适、呕吐和口腔念珠菌病(鹅口疮)。
COPD:SYMBICORT 160/4.5 mcg is used long-term to improve symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, for better breathing and fewer flare-ups. Asthma:SYMBICORT is for the treatment of asthma in patients 6 years and older whose asthma is no...